Irol 2002, seventy six:1914-1921. Cobbold S, Waldmann H: Infectious tolerance. Curr Opin Immunol 1998, 10:518-524. Martin E, O’Sullivan BJ, Lower P, Thomas R: Antigen-specific suppression of a primed immune reaction by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003, 18:155-167. Li M, Zhang X, Zheng X, Lian D, Zhang ZX, Ge W, Yang J, Vladau C, Suzuki M, Chen D, Zhong R, Garcia B, Jevnikar AM, Min WP: Immune modulation and tolerance induction by RelB-silenced dendritic cells by means of RNA interference. J Immunol 2007, 178:5480-5487. Thompson AG, O’Sullivan BJ, Beamish H, Thomas R: T cells signaled by NF-B- dendritic cells are sensitized not anergic to subsequent activation. J Immunol 2004, 173:1671-1680. Martin E, Capini C, Duggan E, Lutzky VP, Stumbles P, Pettit AR, O’Sullivan B, Thomas R: Antigen-specific suppression of recognized arthritis in mice by dendritic cells deficient in NF-B. Arthritis Rheum 2007, 56:2255-2266. Thomas R, Avenue S, Ramnoruth N, Pahau H, Regulation SC, Brunck M, Hyde C, O’Sullivan BJ, Capini C, Tran A, Ng J, Paul S: Feasibility, protection and clinical effects of a Carbonic Anhydrase 1, Human (His) single intradermal administration of autologous tolerising dendritic cells subjected to citrullinated peptides in individuals with rheumatoid arthritis [abstract]. Arthritis Rheum 2011, sixty three. Yoshimura S, Bonderson J, Brennan FM, Foxwell BM, Feldmann M: Role of NF-B in antigen presentation and growth of regulatory T cells elucidated by remedy of dendritic cells with protease inhibitor PSI. Eur J Immunol 2001, 31:1883-1893.one hundred. Geisel J, Kahl F, Muller M, Wagner H, Kirschning CJ, Autenrieth IB, Frick JS: IL-6 and maturation govern TLR2 and TLR4 induced TLR agonist tolerance and cross-tolerance in dendritic cells. J Immunol 2007, 179:5811-5818. one hundred and one. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW: Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and market organ transplant tolerance. J Immunol 2007, 178:7018-7031. 102. Dong X, Lutz W, Schroeder TM, Bachman LA, Westendorf JJ, Kumar R, Griffin MD: Regulation of relB in dendritic cells by the use of modulated association of vitamin D receptor and histone deacetylase 3 using the promoter. Proc Natl Acad Sci U S A 2005, 102:16007-16012. 103. Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM: Therapeutic effect of tolerogenic dendritic cells in recognized collageninduced arthritis is connected using a reduction in Th17 responses. Arthritis Rheum 2010, 62:3656-3665. 104. Harry RA, Anderson AE, Isaacs JD, Hilkens CM: Technology and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheumatic Dis 2010, 69:2042-2050. one hundred and five. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M: Phase I (protection) examine of autologous tolerogenic dendritic cells in variety one diabetic individuals. Diabetes Treatment PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/10435414 2011, 34:2026-2032. 106. Capini C, Jaturanpinyo M, Chang Hello, Mutalik S, McNally A, Street S, Steptoe R, O’Sullivan B, Davies N, Thomas R: Antigen-specific suppression of inflammatory arthritis working with liposomes. J Immunol 2009, 182:3556-3565. 107. Pack CD, Cestra AE, Min B, Legge KL, Li L, Caprio-Young JC, Bell JJ, Gregg RK, Zaghouani H: Neonatal publicity to antigen primes the immune process to acquire responses in a variety of lymphoid organs and encourages bystander regulation of diverse T mobile specificities. J Immunol 2001, 167:4187-4195. 108. Va.